These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 9614617)

  • 1. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps.
    Melki V; Renard E; Lassmann-Vague V; Boivin S; Guerci B; Hanaire-Broutin H; Bringer J; Belicar P; Jeandidier N; Meyer L; Blin P; Augendre-Ferrante B; Tauber JP
    Diabetes Care; 1998 Jun; 21(6):977-82. PubMed ID: 9614617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study.
    Johansson UB; Adamson UC; Lins PE; Wredling RA
    Diabetes Metab; 2000 May; 26(3):192-6. PubMed ID: 10880892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents.
    Holcombe JH; Zalani S; Arora VK; Mast CJ;
    Clin Ther; 2002 Apr; 24(4):629-38. PubMed ID: 12017407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.
    Hanaire-Broutin H; Melki V; Bessières-Lacombe S; Tauber JP
    Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.
    Roach P; Bai S; Charbonnel B; Consoli A; Taboga C; Tiengo A; Bolli G;
    Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin.
    Tsui EY; Chiasson JL; Tildesley H; Barnie A; Simkins S; Strack T; Zinman B
    Diabetes Care; 1998 Jan; 21(1):93-6. PubMed ID: 9538976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group.
    Holleman F; Schmitt H; Rottiers R; Rees A; Symanowski S; Anderson JH
    Diabetes Care; 1997 Dec; 20(12):1827-32. PubMed ID: 9405901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
    Renner R; Pfützner A; Trautmann M; Harzer O; Sauter K; Landgraf R
    Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of blood glucose stability and HbA1C between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in type 1 diabetic patients: a pilot study.
    Catargi B; Meyer L; Melki V; Renard E; Jeandidier N;
    Diabetes Metab; 2002 Apr; 28(2):133-7. PubMed ID: 11976565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin lispro in CSII: results of a double-blind crossover study.
    Zinman B; Tildesley H; Chiasson JL; Tsui E; Strack T
    Diabetes; 1997 Mar; 46(3):440-3. PubMed ID: 9032100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump.
    Raskin P; Holcombe JH; Tamborlane WV; Malone JI; Strowig S; Ahern JA; Lavent F
    J Diabetes Complications; 2001; 15(6):295-300. PubMed ID: 11711322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [How should we use the short-acting insulin analog Lys-Pro in external continuous subcutaneous pumps?].
    Guerci B; Jeandidier N; Lassmann-Vague V; Renard E; Hanaire-Broutin H
    Diabetes Metab; 2000 Dec; 26(6):513-9. PubMed ID: 11173725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients.
    Schernthaner G; Wein W; Sandholzer K; Equiluz-Bruck S; Bates PC; Birkett MA
    Diabetes Care; 1998 Apr; 21(4):570-3. PubMed ID: 9571344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Special management of insulin lispro in continuous subcutaneous insulin infusion in young diabetic children: a randomized cross-over study.
    Tubiana-Rufi N; Coutant R; Bloch J; Munz-Licha G; Delcroix C; Montaud-Raguideau N; Ducrocq R; Limal JM; Czernichow P
    Horm Res; 2004; 62(6):265-71. PubMed ID: 15523183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
    Roach ; Koledova E; Metcalfe S; Hultman C; Milicevic Z;
    Clin Ther; 2001 Oct; 23(10):1732-44. PubMed ID: 11726007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
    Anderson JH; Brunelle RL; Keohane P; Koivisto VA; Trautmann ME; Vignati L; DiMarchi R
    Arch Intern Med; 1997 Jun; 157(11):1249-55. PubMed ID: 9183237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.